Sanofi Share Holder Equity 2012-2025 | SNY
Sanofi share holder equity from 2012 to 2025. Share holder equity can be defined as the sum of preferred and common equity items
- Sanofi share holder equity for the quarter ending September 30, 2025 was $85.953B, a 0% increase year-over-year.
- Sanofi share holder equity for 2024 was $84.249B, a 4.69% increase from 2023.
- Sanofi share holder equity for 2023 was $80.472B, a 1.63% increase from 2022.
- Sanofi share holder equity for 2022 was $79.18B, a 3.05% decline from 2021.
|
Sanofi Annual Share Holder Equity (Millions of US $) |
|
|---|---|
| 2024 | $84,249 |
| 2023 | $80,472 |
| 2022 | $79,180 |
| 2021 | $81,671 |
| 2020 | $72,133 |
| 2019 | $66,201 |
| 2018 | $69,720 |
| 2017 | $65,849 |
| 2016 | $63,877 |
| 2015 | $64,636 |
| 2014 | $74,797 |
| 2013 | $75,732 |
| 2012 | $73,915 |
| 2011 | $78,539 |
|
Sanofi Quarterly Share Holder Equity (Millions of US $) |
|
|---|---|
| 2025-09-30 | $85,953 |
| 2025-06-30 | $79,781 |
| 2025-03-31 | $78,399 |
| 2024-12-31 | $84,249 |
| 2024-09-30 | |
| 2024-06-30 | $78,610 |
| 2024-03-31 | |
| 2023-12-31 | $80,472 |
| 2023-09-30 | |
| 2023-06-30 | $79,541 |
| 2023-03-31 | |
| 2022-12-31 | $79,180 |
| 2022-09-30 | |
| 2022-06-30 | $75,882 |
| 2022-03-31 | |
| 2021-09-30 | |
| 2021-03-31 | |
| 2020-09-30 | |
| 2020-03-31 | |
| 2019-09-30 | |
| 2019-03-31 | |
| 2018-03-31 | |
| 2017-12-31 | $65,849 |
| 2017-09-30 | |
| 2017-06-30 | $63,583 |
| 2017-03-31 | |
| 2016-12-31 | $63,877 |
| 2016-09-30 | |
| 2016-06-30 | $61,390 |
| 2016-03-31 | |
| 2015-09-30 | |
| 2015-06-30 | $62,803 |
| 2014-06-30 | $71,014 |
| 2013-06-30 | $73,385 |
| 2012-06-30 | $72,421 |
| 2012-03-31 | $0 |
| 2011-12-31 | $78,539 |
| 2011-09-30 | |
| 2011-06-30 | $75,685 |
| 2011-03-31 | |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $115.121B | $44.458B |
| Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $1018.358B | 48.99 |
| Johnson & Johnson (JNJ) | United States | $514.746B | 20.58 |
| AbbVie (ABBV) | United States | $390.150B | 23.36 |
| Roche Holding AG (RHHBY) | Switzerland | $339.804B | 0.00 |
| Novartis AG (NVS) | Switzerland | $299.140B | 15.86 |
| Merck (MRK) | United States | $268.704B | 12.52 |
| Novo Nordisk (NVO) | Denmark | $266.293B | 15.61 |
| Pfizer (PFE) | United States | $142.996B | 7.86 |
| Bayer (BAYRY) | Germany | $44.563B | 7.82 |
| Innoviva (INVA) | United States | $1.459B | 7.31 |